KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Amortization - Intangibles (2019 - 2025)

Supernus Pharmaceuticals has reported Amortization - Intangibles over the past 7 years, most recently at $24.5 million for Q4 2025.

  • Quarterly Amortization - Intangibles rose 34.02% to $24.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $89.4 million through Dec 2025, up 14.67% year-over-year, with the annual reading at $89.5 million for FY2025, 14.69% up from the prior year.
  • Amortization - Intangibles was $24.5 million for Q4 2025 at Supernus Pharmaceuticals, up from $24.3 million in the prior quarter.
  • Over five years, Amortization - Intangibles peaked at $24.5 million in Q4 2025 and troughed at $5.9 million in Q2 2021.
  • The 5-year median for Amortization - Intangibles is $20.1 million (2023), against an average of $18.1 million.
  • Year-over-year, Amortization - Intangibles surged 376.37% in 2021 and then fell 13.27% in 2024.
  • A 5-year view of Amortization - Intangibles shows it stood at $12.0 million in 2021, then skyrocketed by 71.88% to $20.7 million in 2022, then increased by 2.09% to $21.1 million in 2023, then decreased by 13.27% to $18.3 million in 2024, then surged by 34.02% to $24.5 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Amortization - Intangibles are $24.5 million (Q4 2025), $24.3 million (Q3 2025), and $20.8 million (Q2 2025).